AR077972A1 - Anticuerpos contra cdcp1 destinados al tratamiento del cancer - Google Patents
Anticuerpos contra cdcp1 destinados al tratamiento del cancerInfo
- Publication number
- AR077972A1 AR077972A1 ARP100103120A ARP100103120A AR077972A1 AR 077972 A1 AR077972 A1 AR 077972A1 AR P100103120 A ARP100103120 A AR P100103120A AR P100103120 A ARP100103120 A AR P100103120A AR 077972 A1 AR077972 A1 AR 077972A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- intended
- antibodies against
- cancer treatment
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Composicion farmacéutica que comprende el anticuerpo, uso del anticuerpo para la preparacion de un medicamento destinado al tratamiento del cáncer; ácido nucleico codificante del anticuerpo humanizado; vectores de expresion y célula huésped. Reivindicacion 1: Anticuerpo de union específica a CCP1 humana, caracterizado por la union al mismo epítopo que CUB4 (n° de deposito DSM ACC2551) para el tratamiento del cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09011047 | 2009-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR077972A1 true AR077972A1 (es) | 2011-10-05 |
Family
ID=41349259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103120A AR077972A1 (es) | 2009-08-28 | 2010-08-26 | Anticuerpos contra cdcp1 destinados al tratamiento del cancer |
Country Status (9)
Country | Link |
---|---|
US (1) | US8883159B2 (es) |
EP (1) | EP2470206A1 (es) |
JP (1) | JP5680646B2 (es) |
CN (1) | CN102481366A (es) |
AR (1) | AR077972A1 (es) |
CA (1) | CA2770141A1 (es) |
SG (1) | SG178881A1 (es) |
TW (1) | TW201113037A (es) |
WO (1) | WO2011023390A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013102825A1 (en) * | 2012-01-02 | 2013-07-11 | Novartis Ag | Cdcp1 and breast cancer |
WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
CN110234348B (zh) | 2016-12-16 | 2024-06-25 | 蓝鳍生物医药公司 | 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法 |
US10928391B2 (en) * | 2017-06-06 | 2021-02-23 | The Cleveland Clinic Foundation | CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease |
WO2019084319A1 (en) * | 2017-10-25 | 2019-05-02 | The Regents Of The University Of California | ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT AND DETECTION OF CANCER |
CA3118542A1 (en) * | 2018-11-09 | 2020-05-14 | Beth Israel Deaconess Medical Center | Cdcp1-targeted therapies |
WO2023246701A1 (zh) * | 2022-06-20 | 2023-12-28 | 四川汇宇制药股份有限公司 | 一种抗体及其用途 |
KR20240057529A (ko) * | 2022-10-24 | 2024-05-03 | 주식회사 노벨티노빌리티 | 신규 항-cdcp1 항체 및 이의 용도 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
CN1329061A (zh) | 2000-06-19 | 2002-01-02 | 上海博德基因开发有限公司 | 一种新的多肽——人g蛋白亚基9.46和编码这种多肽的多核苷酸 |
EP1301533A1 (de) | 2000-07-07 | 2003-04-16 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4 |
JP2005532253A (ja) | 2001-10-25 | 2005-10-27 | ジェネンテック・インコーポレーテッド | 糖タンパク質組成物 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
DE10242146A1 (de) | 2002-09-04 | 2004-03-18 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen |
KR101498588B1 (ko) | 2003-01-22 | 2015-03-05 | 로슈 글리카트 아게 | 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도 |
MXPA05008794A (es) | 2003-02-19 | 2006-03-10 | Novartis Ag | Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas. |
EP1648511A1 (en) | 2003-07-29 | 2006-04-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
EP1664116A4 (en) | 2003-08-22 | 2009-06-03 | Biogen Idec Inc | IMPROVED ANTIBODIES WITH CHANGED EFFECTOR FUNCTION AND MANUFACTURING METHOD THEREFOR |
EP1663306A2 (en) | 2003-09-05 | 2006-06-07 | Genentech, Inc. | Antibodies with altered effector functions |
GB0324656D0 (en) | 2003-10-22 | 2003-11-26 | Celltech R&D Ltd | A protein involved in ovarian cancer |
CN102373214B (zh) | 2003-11-05 | 2014-07-09 | 罗氏格黎卡特股份公司 | 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 |
US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
CA2606102C (en) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
EP1877441A2 (en) | 2005-04-26 | 2008-01-16 | Bioren, Inc. | Method of producing human igg antibodies with enhanced effector functions |
WO2007005502A2 (en) | 2005-06-30 | 2007-01-11 | Applera Corporation | Methods and compositions for treating diseases targeting cdcp1 |
US20070071745A1 (en) | 2005-08-26 | 2007-03-29 | Pablo Umana | Modified antigen binding molecules with altered cell signaling activity |
JP2007112734A (ja) | 2005-10-19 | 2007-05-10 | Chugai Pharmaceut Co Ltd | 抗cdcp1抗体を含有する癌細胞増殖抑制剤 |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
TWI412375B (zh) * | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗cdcp1抗體 |
-
2010
- 2010-08-25 TW TW099128527A patent/TW201113037A/zh unknown
- 2010-08-26 US US12/868,849 patent/US8883159B2/en not_active Expired - Fee Related
- 2010-08-26 EP EP10749787A patent/EP2470206A1/en not_active Withdrawn
- 2010-08-26 CN CN2010800382788A patent/CN102481366A/zh active Pending
- 2010-08-26 AR ARP100103120A patent/AR077972A1/es unknown
- 2010-08-26 CA CA2770141A patent/CA2770141A1/en not_active Abandoned
- 2010-08-26 WO PCT/EP2010/005245 patent/WO2011023390A1/en active Application Filing
- 2010-08-26 SG SG2012013272A patent/SG178881A1/en unknown
- 2010-08-26 JP JP2012525933A patent/JP5680646B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP5680646B2 (ja) | 2015-03-04 |
WO2011023390A1 (en) | 2011-03-03 |
EP2470206A1 (en) | 2012-07-04 |
TW201113037A (en) | 2011-04-16 |
JP2013502905A (ja) | 2013-01-31 |
US20110070246A1 (en) | 2011-03-24 |
US8883159B2 (en) | 2014-11-11 |
CN102481366A (zh) | 2012-05-30 |
CA2770141A1 (en) | 2011-03-03 |
SG178881A1 (en) | 2012-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR077972A1 (es) | Anticuerpos contra cdcp1 destinados al tratamiento del cancer | |
CL2017001580A1 (es) | Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped. | |
CL2012003283A1 (es) | Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8. | |
CL2012003054A1 (es) | Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión. | |
BR112017010110A2 (pt) | anticorpos contra cd73 e usos do mesmo | |
SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
PH12015501092A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
AR074563A1 (es) | Anticuerpos anti ligando 1 de muerte programada (anti-pd-l1) y su uso para mejorar la funcion de las celulas t | |
EP3539988A3 (en) | Monoclonal antibodies against her2 | |
MX348578B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
NZ607969A (en) | Cd33 binding agents | |
UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
MX351682B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
AR101669A1 (es) | Constructos de anticuerpos para cdh19 y cd3 | |
BR112012018951B8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
CO6612271A2 (es) | Anticuerpos anti-cd40 | |
MX2010009190A (es) | Anticuerpos anti-c5ar humanizados. | |
CL2011002756A1 (es) | Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |